The role of cerebrospinal fluid and other biomarker modalities in the Alzheimer's disease diagnostic revolution.
Level V
Where this comes from
- Record sourced from PubMed, PMID 37202514.
- Also identified by DOI 10.1038/s43587-023-00400-6 and PMC identifier 10720501.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A major transformation in dementia diagnosis and care appears imminent and will depend on three major types of biomarkers: molecular imaging, blood-based biomarkers, and cerebrospinal fluid biomarkers. Each modality has unique strengths and limitations that suggest its optimal uses in research, clinical trials, and clinical diagnosis.
Medical subject headings
- Alzheimer Disease